Author

Tsugiko Oze

Observed names: T OZE, T. Oze, オゼ, ツギコ

Observed institutions: Heidelberg University, The Royal Free Hospital, Osaka National Hospital, Osaka Minami Medical Center, University College London, The University of Osaka

OpenAlex ID: A5043392003

Post-treatment Levels of α-Fetoprotein Predict Incidence of Hepatocellular Carcinoma After Interferon Therapy

2013 · Tsugiko Oze, Naoki Hiramatsu, et al. · Clinical Gastroenterology and Hepatology · 110

PDF

Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon‐based antiviral therapy

2014 · Naoki Hiramatsu, Tsugiko Oze, et al. · Hepatology Research · 81

Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin

2009 · N. Hiramatsu, T. Oze, et al. · Journal of Viral Hepatitis · 68

Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis

2013 · Naoki Morishita, Naoki Hiramatsu, et al. · Journal of Gastroenterology · 65

Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection

2012 · Mika Kurokawa, Naoki Hiramatsu, et al. · Journal of Gastroenterology · 59

Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection

2012 · Koyo Higashitani, Tatsuya Kanto, et al. · Journal of Gastroenterology · 48

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy

2010 · Tsugiko Oze, Naoki Hiramatsu, et al. · Journal of Hepatology · 45

Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection

2014 · the Osaka Liver Forum, Ryoko Yamada, et al. · Journal of Gastroenterology · 38

Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response

2019 · Ryoko Yamada, Naoki Hiramatsu, et al. · Hepatology Research · 36

Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

2006 · N HIRAMATSU, T OZE, et al. · Hepatology Research · 35

Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment

2017 · Yugo Kai, Hayato Hikita, et al. · Scientific Reports · 33

PDF

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses

2009 · Y. Inoue, N. Hiramatsu, et al. · Journal of Viral Hepatitis · 33

Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

2009 · Mika Kurokawa, Naoki Hiramatsu, et al. · Hepatology Research · 33

Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice

2015 · Yugo Kai, Hayato Hikita, et al. · Journal of Gastroenterology · 31

Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection

2006 · T YAKUSHIJIN, T KANTO, et al. · Hepatology Research · 31

Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin

2009 · T. Oze, N. Hiramatsu, et al. · Journal of Viral Hepatitis · 29

Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C

2007 · Naoki Hiramatsu, Nao Kurashige, et al. · Hepatology Research · 24

Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C

2006 · Tsugiko Oze, Naoki Hiramatsu, et al. · Journal of Gastroenterology · 22

Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma

2012 · Keisuke Kohga, Tomohide Tatsumi, et al. · Cancer Immunology Immunotherapy · 21

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan

2011 · Tsugiko Oze, Naoki Hiramatsu, et al. · Journal of Gastroenterology · 18

Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study

2024 · Machiko Kai, Hayato Hikita, et al. · PLoS ONE · 17

PDF

Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients

2013 · Ryoko Yamada, Naoki Hiramatsu, et al. · Journal of Medical Virology · 17

A New Prognostic System for Hepatocellular Carcinoma Including Recurrent Cases: A Study of 861 Patients in a Single Institution

2008 · Takashi Toyama, Naoki Hiramatsu, et al. · Journal of Clinical Gastroenterology · 16

Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C

2013 · Kazuto Fukuda, Yasuharu Imai, et al. · Hepatology Research · 14

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

2011 · Tsugiko Oze, Naoki Hiramatsu, et al. · Journal of Gastroenterology · 13

Works count: 61

Citation count: 1,098

H-index: 19

I10-index: 34